TADOCIZUMAB

UNII: R34T642CGV
Preferred Substance Name: TADOCIZUMAB

339086-80-5
C4G1
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTEGRIN .ALPHA.IIB.BETA.3) FAB FRAGMENT (HUMAN-MOUSE MONOCLONAL C4G1 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL C4G1 .KAPPA.-CHAIN
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTEGRIN .ALPHA.IIB.BETA.3) FAB FRAGMENT (HUMAN-MOUSE MONOCLONAL C4G1 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL C4G1 .KAPPA.-CHAIN
TADOCIZUMAB [INN]
TADOCIZUMAB [USAN]
YM337
YM-337

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

TADOCIZUMAB

Synonyms and Mappings

Resources

Note